NAS:FLGT (USA) Also trade in: Germany

Fulgent Genetics Inc

$ 6.19 -0.21 (-3.27%)
Volume: 371 Avg Vol (1m): 11,556
Market Cap $: 113.44 Mil Enterprise Value $: 84.01 Mil
P/E (TTM): 0.00 P/B: 2.28
Earnings Power Value 0
Net Current Asset Value 1.68
Tangible Book 2.74
Projected FCF 0
Median P/S Value 5.32
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9.2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
N/A
Equity-to-Asset 0.90
Equity-to-Asset range over the past 10 years
Min: 0.76, Med: 0.94, Max: 0.96
Current: 0.9
0.76
0.96
Interest Coverage No Debt
N/A
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 12.14
DISTRESS
GREY
SAFE
Beneish M-Score -3.24
Not Manipulator
Manipulator

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -21.29
Operating Margin range over the past 10 years
Min: -77.46, Med: -23.75, Max: 5.02
Current: -21.29
-77.46
5.02
Net Margin % -25.40
Net Margin range over the past 10 years
Min: -335.13, Med: -29.26, Max: -13.4
Current: -25.4
-335.13
-13.4
ROE % -10.81
ROE range over the past 10 years
Min: -254.33, Med: -45.84, Max: -4.62
Current: -10.81
-254.33
-4.62
ROA % -10.18
ROA range over the past 10 years
Min: -209.1, Med: -16.74, Max: -4.36
Current: -10.18
-209.1
-4.36
ROC (Joel Greenblatt) % -40.85
ROC (Joel Greenblatt) range over the past 10 years
Min: -190.32, Med: -45.32, Max: 14.84
Current: -40.85
-190.32
14.84
3-Year Total Revenue Growth Rate 30.60
3-Year Revenue Growth Rate range over the past 10 years
Min: 16.6, Med: 68, Max: 119.4
Current: 16.6
16.6
119.4
3-Year Total EBITDA Growth Rate 13.10
3-Year EBITDA Growth Rate range over the past 10 years
Min: -16.9, Med: 2.8, Max: 22.5
Current: 22.5
-16.9
22.5
3-Year EPS w/o NRI Growth Rate 0.70
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0.35, Max: 0.7
Current: 0.7
0
0.7

» FLGT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:FLGT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Medical Diagnostics & Research    NAICS : 621511    SIC : 8071
Compare NAS:ITUS OSL:GENT-ME AMEX:VNRX NAS:MOTS ROCO:6598 ROCO:6615 XKRX:109820 XKRX:238120 LSE:AGL SGX:1B1 XPAR:CLNV BOM:524394 TPE:4155 ASX:VHT WAR:VOX TSE:3386 XKRX:084650 TSXV:PRN XTER:LIO1 ASX:CMP
Traded in other countries 7F0.Germany
Address 4978 Santa Anita Avenue, Temple City, CA, USA, 91780
Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care.

Ratios

Current vs industry vs history
PB Ratio 2.28
PB Ratio range over the past 10 years
Min: 1.05, Med: 1.62, Max: 9.88
Current: 2.28
1.05
9.88
PS Ratio 5.09
PS Ratio range over the past 10 years
Min: 2.7, Med: 4.36, Max: 11.19
Current: 5.09
2.7
11.19
Price-to-Operating-Cash-Flow 67.26
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 15.16, Med: 40.61, Max: 74.46
Current: 67.26
15.16
74.46
EV-to-EBIT -17.88
EV-to-EBIT range over the past 10 years
Min: -454.5, Med: -7.3, Max: 237.5
Current: -17.88
-454.5
237.5
EV-to-EBITDA -33.40
EV-to-EBITDA range over the past 10 years
Min: -37.9, Med: -9.8, Max: 104.4
Current: -33.4
-37.9
104.4
EV-to-Revenue 3.79
EV-to-Revenue range over the past 10 years
Min: 1.2, Med: 3, Max: 11.9
Current: 3.79
1.2
11.9
Current Ratio 11.33
Current Ratio range over the past 10 years
Min: 1.63, Med: 10.58, Max: 18.2
Current: 11.33
1.63
18.2
Quick Ratio 11.33
Quick Ratio range over the past 10 years
Min: 1.63, Med: 10.58, Max: 18.2
Current: 11.33
1.63
18.2
Days Sales Outstanding 75.47
Days Sales Outstanding range over the past 10 years
Min: 75.47, Med: 87.16, Max: 110.53
Current: 75.47
75.47
110.53
Days Payable 48.79
Days Payable range over the past 10 years
Min: 22.61, Med: 64.34, Max: 149.65
Current: 48.79
22.61
149.65

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -12.10
3-Year Share Buyback Rate range over the past 10 years
Min: -12.1, Med: -11.95, Max: -11.8
Current: -12.1
-12.1
-11.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.26
Price-to-Tangible-Book range over the past 10 years
Min: 1.12, Med: 1.56, Max: 9.33
Current: 2.26
1.12
9.33
Price-to-Median-PS-Value 1.16
Price-to-Median-PS-Value range over the past 10 years
Min: 0.61, Med: 0.97, Max: 2.17
Current: 1.16
0.61
2.17
Earnings Yield (Joel Greenblatt) % -5.61
Earnings Yield (Greenblatt) range over the past 10 years
Min: -25.1, Med: -6.6, Max: 2.1
Current: -5.61
-25.1
2.1

More Statistics

Revenue (TTM) (Mil) $ 22.07
EPS (TTM) $ -0.24
Beta 0
Volatility % 53.52
52-Week Range $ 3.02 - 7.85
Shares Outstanding (Mil) 18.32

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y